

Pharmacy Program Quarterly Update

Changes Effective Oct. 1, 2026 – Part 2

Oct. 9, 2026

Contents

Drug List Changes

Drug List Additions

- Balanced Drug List Additions

- Performance and Performance Annual Drug List Additions

- Performance Select Drug List Additions

- Basic, Basic Annual, Basic Multi-Tier, Basic Multi-Tier Annual, Enhanced, Enhanced Annual, Enhanced Multi-Tier and Enhanced Multi-Tier Annual Drug Lists Additions

Other Drug List Additions

- Balanced Drug List Additions

- Performance Drug List Additions

- Performance Select Drug List Additions

- Basic, Basic Annual, Basic Multi-Tier, Basic Multi-Tier Annual, Enhanced, Enhanced Annual and Enhanced Multi-Tier Annual Drug List Additions

Drug Tier Changes

- Balanced Drug List Tier Changes

- Performance and Performance Annual Drug List Tier Changes

- Performance Select Drug List Tier Changes

Other Tier Changes

- Balanced Drug list Tier Changes

- Performance Drug List Tier Changes

- Performance Full Drug List Tier Changes

- Performance Select Drug List Tier Changes

Utilization Management Program Changes

Standard Utilization Management Program Updates

Dispensing Limit Changes

- Basic, Basic Multi-Tier, Enhanced, Enhanced Multi-Tier, Basic Annual, Basic Multi-Tier Annual, Enhanced Annual, Enhanced Multi-Tier Annual, HIM, Balanced, Performance, Performance Annual, Performance Full, Performance Select Drug lists

Change in Benefit Coverage for Select High-Cost Products

Reminder: Quarterly Pharmacy Changes are published in two parts. This part 2 article contains coverage additions, utilization management updates and other pharmacy program updates. These updates do not require member notification. The part 1 article covers changes that require member notification – drug list revisions/exclusions, dispensing limits, utilization-management changes and general information on pharmacy benefit program updates. Our members receive letters regarding these changes.

Drug List Changes

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some additions (new to coverage) and/or some coverage tier changes (drugs moved to a lower out-of-pocket payment level) will be made to the Blue Cross and Blue Shield of Texas drug lists. **Additions effective Oct. 1, 2026, and prior updates are outlined below.**

Drug List Additions

BALANCED DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
ATMEKSI (methocarbamol oral susp 750 mg/5 mL)	Muscle Spasms
BREZTRI AEROSPHERE (budesonide-glycopyrrolate-formoterol aers 160-18-4.8 mcg/act)	Asthma
DESMODA (desmopressin acetate oral soln 0.05 mg/mL)	Arginine vasopressin deficiency
esomeprazole magnesium cap DR 20 mg, 40 mg	Gastroesophageal reflux disease (GERD)
JAVADIN (clonidine HCl oral soln 100 mcg/5 mL)	Hypertension
lansoprazole cap 15 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap DR 30 mg	Gastroesophageal reflux disease (GERD)
LEQEMBI IQLIK (lecanemab-irmb soln auto-inj 2 x 250 mg/1.25 mL (500 mg dose))	Alzheimer's disease
LEQEMBI IQLIK (lecanemab-IRMB soln auto-inj 360 mg/1.8 mL)	Alzheimer's disease
nystatin-triamcinolone cream 100000-0.1 unit/gm-%	candidiasis
nystatin-triamcinolone oint 100000-0.1 unit/gm-%	candidiasis
ONTRALFY (tizanidine HCl oral soln 2 mg/5 mL)	Spasticity
PIVYA (pivmecillinam HCl tab 185 mg)	Uncomplicated urinary tract infection
QELBREE (viloxazine HCl cap ER 100 mg, 150 mg, 200 mg)	ADHD
RANITIDINE HYDROCHLORIDE (ranitidine HCl tab 150 mg, 300 mg)	Gastroesophageal reflux disease (GERD)
REZENOPY (naloxone HCl nasal spray 10 mg/0.11 mL)	Opioid overdose
SDAMLO (amlodipine besylate for oral soln 2.5 mg, 5 mg, 10 mg)	Hypertension
STEQEYMA (ustekinumab-stba subcutaneous soln 45 mg/0.5 mL)	Autoimmune disorders
YUVEZZI (carbachol-brimonidine tartrate ophth soln 2.75-0.1%)	Presbyopia

BALANCED BIOSIMILAR DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
ATMEKSI (methocarbamol oral susp 750 mg/5 mL)	Muscle Spasms
BREZTRI AEROSPHERE (budesonide-glycopyrrolate-formoterol aers 160-18-4.8 mcg/act)	Asthma
DESMODA (desmopressin acetate oral soln 0.05 mg/mL)	Arginine vasopressin deficiency
esomeprazole magnesium cap DR 20 mg, 40 mg (base equivalent)	Gastroesophageal reflux disease (GERD)

BALANCED BIOSIMILAR DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
JAVADIN (clonidine HCl oral soln 100 mcg/5 mL)	Hypertension
lansoprazole cap 15 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap DR 30 mg	Gastroesophageal reflux disease (GERD)
LEQEMBI IQLIK (lecanemab-irmb soln auto-inj 2 x 250 mg/1.25 mL (500 mg dose))	Alzheimer's disease
LEQEMBI IQLIK (lecanemab-IRMB soln auto-inj 360 mg/1.8 mL)	Alzheimer's disease
nystatin-triamcinolone cream 100000-0.1 unit/gm-%	candidiasis
nystatin-triamcinolone oint 100000-0.1 unit/gm-%	candidiasis
ONTRALFY (tizanidine HCl oral soln 2 mg/5 mL)	Spasticity
PIVYA (pivmecillinam HCl tab 185 mg)	Uncomplicated urinary tract infection
QELBREE (viloxazine HCl cap ER 100 mg, 150 mg, 200 mg)	ADHD
RANITIDINE HYDROCHLORIDE (ranitidine HCl tab 150 mg, 300 mg)	Gastroesophageal reflux disease (GERD)
REZENOPY (naloxone HCl nasal spray 10 mg/0.11 mL)	Opioid overdose
SDAMLO (amlodipine besylate for oral soln 2.5 mg, 5 mg, 10 mg)	Hypertension
STEQEYMA (ustekinumab-stba subcutaneous soln 45 mg/0.5 mL)	Autoimmune disorders
YUVEZZI (carbachol-brimonidine tartrate ophth soln 2.75-0.1%)	Presbyopia

PERFORMANCE AND PERFORMANCE ANNUAL DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
BREZTRI AEROSPHERE (budesonide-glycopyrrolate-formoterol aers 160-18-4.8 mcg/act)	Asthma
esomeprazole magnesium cap DR 20 mg, 40 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap 15 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap DR 30 mg	Gastroesophageal reflux disease (GERD)
LEQEMBI IQLIK (lecanemab-irmb soln auto-inj 2 x 250 mg/1.25 mL (500 mg dose))	Alzheimer's disease
LEQEMBI IQLIK (lecanemab-IRMB soln auto-inj 360 mg/1.8 mL)	Alzheimer's disease
nystatin-triamcinolone cream 100000-0.1 unit/gm-%	candidiasis
nystatin-triamcinolone oint 100000-0.1 unit/gm-%	candidiasis
REZENOPY (naloxone HCl nasal spray 10 mg/0.11 mL)	Opioid overdose
STEQEYMA (ustekinumab-stba subcutaneous soln 45 mg/0.5 mL)	Autoimmune disorders

PERFORMANCE BIOSIMILAR DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
BREZTRI AEROSPHERE (budesonide-glycopyrrolate-formoterol aers 160-18-4.8 mcg/act)	Asthma
esomeprazole magnesium cap DR 20 mg, 40 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap 15 mg	Gastroesophageal reflux disease (GERD)

PERFORMANCE BIOSIMILAR DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
lansoprazole cap DR 30 mg	Gastroesophageal reflux disease (GERD)
LEQEMBI IQLIK (lecanemab-IRMB soln auto-inj 250 mg/1.8 mL, 360 mg/1.8 mL)	Alzheimer's disease
nystatin-triamcinolone cream 100000-0.1 unit/gm-%	candidiasis
nystatin-triamcinolone oint 100000-0.1 unit/gm-%	candidiasis
REZENOPY (naloxone HCl nasal spray 10 mg/0.11 mL)	Opioid overdose
STEQEYMA (ustekinumab-stba subcutaneous soln 45 mg/0.5 mL)	Autoimmune disorders

PERFORMANCE SELECT DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
BREZTRI AEROSPHERE (budesonide-glycopyrrolate-formoterol aers 160-18-4.8 mcg/act)	Asthma
esomeprazole magnesium cap DR 20 mg, 40 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap 15 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap DR 30 mg	Gastroesophageal reflux disease (GERD)
LEQEMBI IQLIK (lecanemab-irmb soln auto-inj 2 x 250 mg/1.25 mL (500 mg dose))	Alzheimer's disease
LEQEMBI IQLIK (lecanemab-irmb soln auto-inj 360 mg/1.8 mL)	Alzheimer's disease
nystatin-triamcinolone cream 100000-0.1 unit/gm-%	candidiasis
nystatin-triamcinolone oint 100000-0.1 unit/gm-%	candidiasis
QELBREE (viloxazine HCl cap ER 100 mg, 150 mg, 200 mg)	ADHD
REZENOPY (naloxone HCl nasal spray 10 mg/0.11 mL)	Opioid overdose
STEQEYMA (ustekinumab-stba subcutaneous soln 45 mg/0.5 mL)	Autoimmune disorders

PERFORMANCE SELECT BIOSIMILAR DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
BREZTRI AEROSPHERE (budesonide-glycopyrrolate-formoterol aers 160-18-4.8 mcg/act)	Asthma
esomeprazole magnesium cap DR 20 mg, 40 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap 15 mg	Gastroesophageal reflux disease (GERD)
lansoprazole cap DR 30 mg	Gastroesophageal reflux disease (GERD)
LEQEMBI IQLIK (lecanemab-irmb soln auto-inj 2 x 250 mg/1.25 mL (500 mg dose))	Alzheimer's disease
LEQEMBI IQLIK (lecanemab-IRMB soln auto-inj 360 mg/1.8 mL)	Alzheimer's disease
nystatin-triamcinolone cream 100000-0.1 unit/gm-%	candidiasis
nystatin-triamcinolone oint 100000-0.1 unit/gm-%	candidiasis

PERFORMANCE SELECT BIOSIMILAR DRUG LIST ADDITIONS	
DRUG ¹	CONDITION
QELBREE (viloxazine HCl cap ER 100 mg, 150 mg, 200 mg)	ADHD
REZENOPY (naloxone HCl nasal spray 10 mg/0.11 mL)	Opioid overdose
STEQEYMA (ustekinumab-stba subcutaneous soln 45 mg/0.5 mL)	Autoimmune disorders

BASIC, BASIC ANNUAL, BASIC MULTI-TIER, BASIC MULTI-TIER ANNUAL, ENHANCED, ENHANCED ANNUAL, ENHANCED MULTI-TIER AND ENHANCED MULTI-TIER ANNUAL DRUG LISTS ADDITIONS	
DRUG ¹	CONDITION
AVTOZMA (tocilizumab-anoh subcutaneous soln auto-inj 162 mg/0.9mL)	Autoimmune Disorders
AVTOZMA (tocilizumab-anoh subcutaneous soln pref syringe 162 mg/0.9 mL)	Autoimmune Disorders
BREZTRI AEROSPHERE (budesonide-glycopyrrolate-formoterol aers 160-18-4.8 mcg/act)	Asthma
FIASP PUMPCART (insulin aspart (with niacinamide) soln cartridge 100 unit/ml)	Diabetes
INGREZZA (valbenazine tosylate cap 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease
INGREZZA (valbenazine tosylate cap therapy pack 40 mg (7) & 80 mg (21))	Tardive Dyskinesia, Chorea associated with Huntington's Disease
INGREZZA (valbenazine tosylate capsule sprinkle 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease
LEQEMBI IQLIK (lecanemab-irmb soln auto-inj 2 x 250 mg/1.25ml (500 mg dose))	Alzheimer's Disease
LEQEMBI IQLIK (lecanemab-IRMB soln auto-inj 360 mg/1.8 mL)	Alzheimer's Disease
PROPRANOLOL HYDROCHLORIDE (propranolol HCl oral soln 20 mg/5 mL)	Hypertension, Infantile Hemangiomas
REZENOPY (naloxone hcl nasal spray 10 mg/0.11 mL)	Opioid Overdose
RHAPSIDO (remibrutinib tab 25 mg)	Chronic spontaneous urticaria
SAPHNELO (anifrolumab-fnia soln prefilled syringe 120 mg/0.8ml)	Lupus
STEQEYMA (ustekinumab-stba subcutaneous soln 45 mg/0.5 mL)	Autoimmune Disorders

Other Drug List Additions

Most additions to the drug list become effective quarterly, however, some drugs are added as part of formulary maintenance (e.g., new strength of covered drug) or re-evaluated during the quarter then added to the list. Those drugs are listed below.

BALANCED DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
albuterol sulfate inhal aero 108 mcg/act (90 mcg base equiv)	Asthma	7/26/26
AMERITHROID (thyroid tab 15 mg (1/4 grain), 30 mg (1/2 grain), 60 mg (1 grain), 90 mg (1 1/2 grain), 120 mg (2 grain), 180 mg (3 grain), 240 mg (4 grain), 300 mg (5 grain))	Hypothyroidism	7/12/26

BALANCED DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
AMOXICILLIN (amoxicillin (trihydrate) chew tab 125 mg, 250 mg)	Bacterial Infections	8/9/26
AMOXICILLIN/POTASSIUM CLAVULANATE (amoxicillin & k clavulanate chew tab 200-28.5 mg, 400-57 mg)	Bacterial Infections	8/9/26
AQVESME (mitapivat sulfate tab 100 mg)	Alpha- or Beta-thalassemia-associated anemia	8/1/26
BESREMI PEN (ropeginterferon alfa-2b-njft soln pen inj 500 mcg/0.5 mL)	Polycythemia Vera	7/19/26
BUCAPSOL (buspirone hcl cap 5 mg)	Anxiety	8/2/26
CARDAMYST (etripamil nasal soln 2 x 70 mg/dose)	Paroxysmal supraventricular tachycardia (PSVT)	8/1/26
CEFPODOXIME PROXETIL (cefpodoxime proxetil for susp 50 mg/5 mL)	Bacterial Infections	7/26/26
dextromethorphan hbr-quinidine sulfate cap 20-10 mg	Pseudobulbar Affect	7/26/26
DIPHENHYDRAMINE HYDROCHLORIDE (diphenhydramine HCl elixir 12.5 mg/5 mL)	Allergic symptoms	8/16/26
FLUAD 2026-2027 (influenza vaccine type a & b surface ant adj susp pref syringe 0.5 mL)	Flu Vaccine	7/12/26
FLUARIX 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUBLOK 2026-2027 (influenza virus vaccine recombinant HA PF soln pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUCELVAX 2026-2027 (influenza virus vaccine tissue-culture subunit susp pref syringe 0.5 mL)	Flu Vaccine	7/12/26
FLULAVAL 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/26/26
FLUMIST NASAL VACCINE 2026-2027 (influenza virus vaccine live intranasal liquid)	Flu Vaccine	8/2/26
FLUZONE 2026-2027 (influenza virus vaccine split IM susp)	Flu Vaccine	7/19/26
FLUZONE 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUZONE HIGH-DOSE 2026-2027 (influenza virus vaccine split high-dose PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FUROSCIX READYFLOW (furosemide subcutaneous soln auto-injector 80 mg/mL)	Fluid Overload Congestion Due to Heart Failure	8/9/26
HYRNUO (sevabertinib tab 10 mg)	Cancer	8/1/26
mesalamine cap ER 250 mg	Ulcerative Colitis	7/26/26
MFLUSIVA 2026-27 (influenza virus vaccine type a & b mrna susp pref syringe 0.38 mL)	Flu Vaccine	8/9/26
MYQORZO (aficamten tab 5 mg, 10 mg, 15 mg, 20 mg)	Obstructive hypertrophic cardiomyopathy	9/1/26

BALANCED DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
PELLIX (calcipotriene soln 0.005% (50 mcg/mL))	Scalp Psoriasis	7/5/26
PENICILLIN V POTASSIUM (penicillin v potassium for soln 125 mg/5 mL, 250 mg/5 mL)	Bacterial Infections	8/16/26
PREDNISONE DR (prednisone tab delayed release 5 mg)	Inflammatory Conditions	8/16/26
rifapentine tab 150 mg	Tuberculosis	8/2/26
sitagliptin phosphate-metformin hcl tab ER 24 hr 50-500 mg, 50-1000 mg, 100-1000 mg	Type 2 diabetes mellitus	8/2/26
SKYRIZI (risankizumab-rzaa soln prefilled syringe 55 mg/0.37 mL)	Autoimmune Disorders	7/12/26
TAPENTADOL HYDROCHLORIDE (tapentadol hcl soln 20 mg/mL (base equivalent))	Pain	7/19/26
TRYNGOLZA (olezarsen sod subcut soln auto-inject 50 mg/0.8 mL (base equivalent))	Familial chylomicronemia syndrome	7/5/26
UPTRAVI (selexipag tab 100 mcg, 150 mcg)	Pulmonary Arterial Hypertension	8/2/26
URSOLIGN (ursodiol cap 150 mg)	Primary Biliary Cholangitis, Gallstone Dissolution	7/26/26
ZYCUBO (copper histidinate for subcutaneous soln 2.9 mg)	Menkes disease	9/1/26

BALANCED BIOSIMILAR DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
albuterol sulfate inhal aero 108 mcg/act (90 mcg base equiv)	Asthma	7/26/26
AMERITHROID (thyroid tab 15 mg (1/4 grain), 30 mg (1/2 grain), 60 mg (1 grain), 90 mg (1 1/2 grain), 120 mg (2 grain), 180 mg (3 grain), 240 mg (4 grain), 300 mg (5 grain))	Hypothyroidism	7/12/26
AMOXICILLIN (amoxicillin (trihydrate) chew tab 125 mg, 250 mg)	Bacterial Infections	8/9/26
AQVESME (mitapivat sulfate tab 100 mg)	Alpha- or Beta-thalassemia-associated anemia	8/1/26
BESREMI PEN (ropeginterferon alfa-2b-njft soln pen inj 500 mcg/0.5 mL)	Polycythemia Vera	7/19/26
BUCAPSOL (buspirone hcl cap 5 mg)	Anxiety	8/2/26
CARDAMYST (etripamil nasal soln 2 x 70 mg/dose)	Paroxysmal supraventricular tachycardia (PSVT)	8/1/26
CEFPODOXIME PROXETIL (cefepodoxime proxetil for susp 50 mg/5 mL)	Bacterial Infections	7/26/26
dextromethorphan hbr-quinidine sulfate cap 20-10 mg	Pseudobulbar Affect	7/26/26
DIPHENHYDRAMINE HYDROCHLORIDE (diphenhydramine hcl elixir 12.5 mg/5 mL)	Allergic symptoms	8/16/26

BALANCED BIOSIMILAR DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
FLUAD 2026-2027 (influenza vaccine type a & b surface ant adj susp pref syringe 0.5 mL)	Flu Vaccine	7/12/26
FLUARIX 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUARIX 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUBLOK 2026-2027 (influenza virus vaccine recombinant HA PF soln pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUBLOK 2026-2027 (influenza virus vaccine recombinant HA PF soln pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUCELVAX 2026-2027 (influenza virus vaccine tissue-culture subunit susp pref syringe 0.5 mL)	Flu Vaccine	7/12/26
FLUCELVAX 2026-2027 (influenza virus vaccine tissue-culture subunit susp pref syringe 0.5 mL)	Flu Vaccine	7/12/26
FLULAVAL 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/26/26
FLULAVAL 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/26/26
FLUMIST NASAL VACCINE 2026-2027 (influenza virus vaccine live intranasal liquid)	Flu Vaccine	8/2/26
FLUMIST NASAL VACCINE 2026-2027 (influenza virus vaccine live intranasal liquid)	Flu Vaccine	8/2/26
FLUZONE 2026-2027 (influenza virus vaccine split IM susp)	Flu Vaccine	7/19/26
FLUZONE 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUZONE HIGH-DOSE 2026-2027 (influenza virus vaccine split high-dose PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FUROSCIX READYFLOW (furosemide subcutaneous soln auto-injector 80 mg/mL)	Fluid Overload Congestion Due to Heart Failure	8/9/26
HYRNUO (sevabertinib tab 10 mg)	Cancer	8/1/26
mesalamine cap ER 250 mg	Ulcerative Colitis	7/26/26
MFLUSIVA 2026-27 (influenza virus vaccine type a & b mrna susp pref syringe 0.38 mL)	Flu Vaccine	8/9/26
MFLUSIVA 2026-27 (influenza virus vaccine type a & b mrna susp pref syringe 0.38 mL)	Flu Vaccine	8/9/26
MYQORZO (aficamten tab 5 mg, 10 mg, 15 mg, 20 mg)	Obstructive hypertrophic cardiomyopathy	9/1/26
PELLIX (calcipotriene soln 0.005% (50 mcg/mL))	Scalp Psoriasis	7/5/26
PENICILLIN V POTASSIUM (penicillin v potassium for soln 125 mg/5 mL, 250 mg/5 mL)	Bacterial Infections	8/16/26

BALANCED BIOSIMILAR DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
PREDNISONE DR (prednisone tab delayed release 5 mg)	Inflammatory Conditions	8/16/26
rifapentine tab 150 mg	Tuberculosis	8/2/26
sitagliptin phosphate-metformin hcl tab ER 24 hr 50-500 mg, 50-1000 mg, 100-1000 mg	Type 2 diabetes mellitus	8/2/26
SKYRIZI (risankizumab-rzaa soln prefilled syringe 55 mg/0.37 mL)	Autoimmune Disorders	7/12/26
TAPENTADOL HYDROCHLORIDE (tapentadol hcl soln 20 mg/mL (base equivalent))	Pain	7/19/26
TRYNGOLZA (olezarsen sod subcut soln auto-inject 50 mg/0.8 mL (base equivalent))	Familial chylomicronemia syndrome	7/5/26
UPTRAIVI (selexipag tab 100 mcg, 150 mcg)	Pulmonary Arterial Hypertension	8/2/26
URSOLIGN (ursodiol cap 150 mg)	Primary Biliary Cholangitis, Gallstone Dissolution	7/26/26
ZYCUBO (copper histidinate for subcutaneous soln 2.9 mg)	Menkes disease	9/1/26

PERFORMANCE DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
albuterol sulfate inhal aero 108 mcg/act (90 mcg base equiv)	Asthma	7/26/26
AMERITHROID (thyroid tab 15 mg (1/4 grain), 30 mg (1/2 grain), 60 mg (1 grain), 90 mg (1 1/2 grain), 120 mg (2 grain), 180 mg (3 grain), 240 mg (4 grain), 300 mg (5 grain))	Hypothyroidism	7/12/26
AMOXICILLIN (amoxicillin (trihydrate) chew tab 125 mg, 250 mg)	Bacterial Infections	8/9/26
AMOXICILLIN/POTASSIUM CLAVULANATE (amoxicillin & k clavulanate chew tab 200-28.5 mg, 400-57 mg)	Bacterial Infections	8/9/26
AQVESME (mitapivat sulfate tab 100 mg)	Alpha- or Beta-thalassemia-associated anemia	8/1/26
BESREMI PEN (ropeginterferon alfa-2b-njft soln pen inj 500 mcg/0.5 mL)	Polycythemia Vera	7/19/26
CARDAMYST (etripamil nasal soln 2 x 70 mg/dose)	Paroxysmal supraventricular tachycardia (PSVT)	8/1/26
CEFPODOXIME PROXETIL (cefepodoxime proxetil for susp 50 mg/5 mL)	Bacterial Infections	7/26/26
dextromethorphan hbr-quinidine sulfate cap 20-10 mg	Pseudobulbar Affect	7/26/26
FLUAD 2026-2027 (influenza vaccine type a & b surface ant adj susp pref syringe 0.5 mL)	Flu vaccine	7/12/26
FLUARIX 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26

PERFORMANCE DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
FLUBLOK 2026-2027 (influenza virus vaccine recombinant HA PF soln pref syringe 0.5 mL)	Flu vaccine	7/19/26
FLUCELVAX 2026-2027 (influenza virus vaccine tissue-culture subunit susp pref syringe 0.5 mL)	Flu vaccine	7/12/26
FLULAVAL 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/26/26
FLUMIST NASAL VACCINE 2026-2027 (influenza virus vaccine live intranasal liquid)	Flu vaccine	8/2/26
FLUZONE 2026-2027 (influenza virus vaccine split IM susp)	Flu vaccine	7/19/26
FLUZONE 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26
FLUZONE HIGH-DOSE 2026-2027 (influenza virus vaccine split high-dose PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26
FUROSCIX READYFLOW (furosemide subcutaneous soln auto-injector 80 mg/mL)	Fluid Overload Congestion Due to Heart Failure	8/9/26
HYRNUO (sevabertinib tab 10 mg)	Cancer	8/1/26
MFLUSIVA 2026-27 (influenza virus vaccine type a & b mrna susp pref syringe 0.38 mL)	Flu Vaccine	8/9/26
MYQORZO (aficamten tab 5 mg, 10 mg, 15 mg, 20 mg)	Obstructive hypertrophic cardiomyopathy	9/1/26
PENICILLIN V POTASSIUM (penicillin v potassium for soln 125 mg/5 mL, 250 mg/5 mL)	Bacterial Infections	8/16/26
rifapentine tab 150 mg	Tuberculosis	8/2/26
sitagliptin phosphate-metformin hcl tab ER 24 hr 50-500 mg, 50-1000 mg, 100-1000 mg	Type 2 diabetes mellitus	8/2/26
SKYRIZI (risankizumab-rzaa soln prefilled syringe 55 mg/0.37 mL)	Autoimmune Disorders	7/12/26
TRYNGOLZA (olezarsen sod subcut soln auto-inject 50 mg/0.8 mL (base equivalent))	Familial chylomicronemia syndrome	7/5/26
UPTRAVI (selexipag tab 100 mcg, 150 mcg)	Pulmonary Arterial Hypertension	8/2/26
ZYCUBO (copper histidinate for subcutaneous soln 2.9 mg)	Menkes disease	9/1/26

PERFORMANCE BIOSIMILAR DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
albuterol sulfate inhal aero 108 mcg/act (90 mcg base equiv)	Asthma	7/26/26

PERFORMANCE BIOSIMILAR DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
AMERITHROID (thyroid tab 15 mg (1/4 grain), 30 mg (1/2 grain), 60 mg (1 grain), 90 mg (1 1/2 grain), 120 mg (2 grain), 180 mg (3 grain), 240 mg (4 grain), 300 mg (5 grain))	Hypothyroidism	7/12/26
AMOXICILLIN (amoxicillin (trihydrate) chew tab 125 mg, 250 mg)	Bacterial Infections	8/9/26
AMOXICILLIN/POTASSIUM CLAVULANATE (amoxicillin & k clavulanate chew tab 200-28.5 mg, 400-57 mg)	Bacterial Infections	8/9/26
AQVESME (mitapivat sulfate tab 100 mg)	Alpha- or Beta-thalassemia-associated anemia	8/1/26
BESREMI PEN (ropeginterferon alfa-2b-njft soln pen inj 500 mcg/0.5 mL)	Polycythemia Vera	7/19/26
CARDAMYST (etripamil nasal soln 2 x 70 mg/dose)	Paroxysmal supraventricular tachycardia (PSVT)	8/1/26
CEFPODOXIME PROXETIL (cefpodoxime proxetil for susp 50 mg/5 mL)	Bacterial Infections	7/26/26
dextromethorphan hbr-quinidine sulfate cap 20-10 mg	Pseudobulbar Affect	7/26/26
FLUAD 2026-2027 (influenza vaccine type a & b surface ant adj susp pref syringe 0.5 mL)	Flu vaccine	7/12/26
FLUARIX 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26
FLUBLOK 2026-2027 (influenza virus vaccine recombinant HA PF soln pref syringe 0.5 mL)	Flu vaccine	7/19/26
FLUCELVAX 2026-2027 (influenza virus vaccine tissue-culture subunit susp pref syringe 0.5 mL)	Flu vaccine	7/12/26
FLULAVAL 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/26/26
FLUMIST NASAL VACCINE 2026-2027 (influenza virus vaccine live intranasal liquid)	Flu vaccine	8/2/26
FLUZONE 2026-2027 (influenza virus vaccine split IM susp)	Flu vaccine	7/19/26
FLUZONE 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26

PERFORMANCE BIOSIMILAR DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
FLUZONE HIGH-DOSE 2026-2027 (influenza virus vaccine split high-dose PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26
FUROSIX READYFLOW (furosemide subcutaneous soln auto-injector 80 mg/mL)	Fluid Overload Congestion Due to Heart Failure	8/9/26
HYRNUO (sevabertinib tab 10 mg)	Cancer	8/1/26
MFLUSIVA 2026-27 (influenza virus vaccine type a & b MRNA susp pref syringe 0.38 mL)	Flu Vaccine	8/9/26
MYQORZO (aficamten tab 5 mg, 10 mg, 15 mg, 20 mg)	Obstructive hypertrophic cardiomyopathy	9/1/26
PENICILLIN V POTASSIUM (penicillin v potassium for soln 125 mg/5 mL, 250 mg/5 mL)	Bacterial Infections	8/16/26
rifapentine tab 150 mg	Tuberculosis	8/2/26
sitagliptin phosphate-metformin hcl tab ER 24 hr 50-500 mg, 50-1000 mg, 100-1000 mg	Type 2 diabetes mellitus	8/2/26
SKYRIZI (risankizumab-rzaa soln prefilled syringe 55 mg/0.37 mL)	Autoimmune Disorders	7/12/26
TRYNGOLZA (olezarsen sod subcut soln auto-inject 50 mg/0.8 mL (base equivalent))	Familial chylomicronemia syndrome	7/5/26
UPTRA VI (selexipag tab 100 mcg, 150 mcg)	Pulmonary Arterial Hypertension	8/2/26
ZYCUBO (copper histidinate for subcutaneous soln 2.9 mg)	Menkes disease	9/1/26

PERFORMANCE SELECT DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
albuterol sulfate inhal aero 108 mcg/act (90 mcg base equiv)	Asthma	7/26/26
AMERITHROID (thyroid tab 15 mg (1/4 grain), 30 mg (1/2 grain), 60 mg (1 grain), 90 mg (1 1/2 grain), 120 mg (2 grain), 180 mg (3 grain), 240 mg (4 grain), 300 mg (5 grain))	Hypothyroidism	7/12/26
AMOXICILLIN (amoxicillin (trihydrate) chew tab 125 mg, 250 mg)	Bacterial Infections	8/9/26
AMOXICILLIN/POTASSIUM CLAVULANATE (amoxicillin & k clavulanate chew tab 200-28.5 mg, 400-57 mg)	Bacterial Infections	8/9/26

PERFORMANCE SELECT DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
AQVESME (mitapivat sulfate tab 100 mg)	Alpha- or Beta-thalassemia-associated anemia	8/1/26
BESREMI PEN (ropeginterferon alfa-2b-njft soln pen inj 500 mcg/0.5 mL)	Polycythemia Vera	7/19/26
CARDAMYST (etripamil nasal soln 2 x 70 mg/dose)	Paroxysmal supraventricular tachycardia (PSVT)	8/1/26
CEFPODOXIME PROXETIL (cefpodoxime proxetil for susp 50 mg/5 mL)	Bacterial Infections	7/26/26
dextromethorphan hbr-quinidine sulfate cap 20-10 mg	Pseudobulbar Affect	7/26/26
FLUAD 2026-2027 (influenza vaccine type a & b surface ant adj susp pref syringe 0.5 mL)	Flu vaccine	7/12/26
FLUARIX 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26
FLUBLOK 2026-2027 (influenza virus vaccine recombinant HA PF soln pref syringe 0.5 mL)	Flu vaccine	7/19/26
FLUCELVAX 2026-2027 (influenza virus vaccine tissue-culture subunit susp pref syringe 0.5 mL)	Flu vaccine	7/12/26
FLULAVAL 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/26/26
FLUMIST NASAL VACCINE 2026-2027 (influenza virus vaccine live intranasal liquid)	Flu vaccine	8/2/26
FLUZONE 2026-2027 (influenza virus vaccine split IM susp)	Flu vaccine	7/19/26
FLUZONE 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26
FLUZONE HIGH-DOSE 2026-2027 (influenza virus vaccine split high-dose PF susp pref syringe 0.5 mL)	Flu vaccine	7/19/26
FUROSCIX READYFLOW (furosemide subcutaneous soln auto-injector 80 mg/mL)	Fluid Overload Congestion Due to Heart Failure	8/9/26
HYRNUO (sevabertinib tab 10 mg)	Cancer	8/1/26
MFLUSIVA 2026-27 (influenza virus vaccine type a & b mrna susp pref syringe 0.38 mL)	Flu Vaccine	8/9/26
MYQORZO (aficamten tab 5 mg, 10 mg, 15 mg, 20 mg)	Obstructive hypertrophic cardiomyopathy	9/1/26
PENICILLIN V POTASSIUM (penicillin v potassium for soln 125 mg/5 mL, 250 mg/5 mL)	Bacterial Infections	8/16/26
rifapentine tab 150 mg	Tuberculosis	8/2/26
sitagliptin phosphate-metformin hcl tab ER 24 hr 50-500 mg, 50-1000 mg, 100-1000 mg	Type 2 diabetes mellitus	8/2/26

PERFORMANCE SELECT DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
SKYRIZI (risankizumab-rzaa soln prefilled syringe 55 mg/0.37 mL)	Autoimmune Disorders	7/12/26
TRYNGOLZA (olezarsen sod subcut soln auto-inject 50 mg/0.8 mL (base equivalent))	Familial chylomicronemia syndrome	7/5/26
UPTRAVI (selexipag tab 100 mcg, 150 mcg)	Pulmonary Arterial Hypertension	8/2/26
ZYCUBO (copper histidinate for subcutaneous soln 2.9 mg)	Menkes disease	9/1/26

PERFORMANCE SELECT BIOSIMILAR DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
albuterol sulfate inhal aero 108 mcg/act (90 mcg base equiv)	Asthma	7/26/26
AMERITHROID (thyroid tab 15 mg (1/4 grain), 30 mg (1/2 grain), 60 mg (1 grain), 90 mg (1 1/2 grain), 120 mg (2 grain), 180 mg (3 grain), 240 mg (4 grain), 300 mg (5 grain))	Hypothyroidism	7/12/26
AMOXICILLIN (amoxicillin (trihydrate) chew tab 125 mg, 250 mg)	Bacterial Infections	8/9/26
AMOXICILLIN/POTASSIUM CLAVULANATE (amoxicillin & k clavulanate chew tab 200-28.5 mg, 400-57 mg)	Bacterial Infections	8/9/26
AQVESME (mitapivat sulfate tab 100 mg)	Alpha- or Beta-thalassemia-associated anemia	8/1/26
BESREMI PEN (ropeginterferon alfa-2b-njft soln pen inj 500 mcg/0.5 mL)	Polycythemia Vera	7/19/26
CARDAMYST (etripamil nasal soln 2 x 70 mg/dose)	Paroxysmal supraventricular tachycardia (PSVT)	8/1/26
CEFPODOXIME PROXETIL (cefepodoxime proxetil for susp 50 mg/5 mL)	Bacterial Infections	7/26/26
dextromethorphan hbr-quinidine sulfate cap 20-10 mg	Pseudobulbar Affect	7/26/26
FLUAD 2026-2027 (influenza vaccine type a & b surface ant adj susp pref syringe 0.5 mL)	Flu vaccine	7/12/26
FLUARIX 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUBLOK 2026-2027 (influenza virus vaccine recombinant HA PF soln pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FLUCELVAX 2026-2027 (influenza virus vaccine tissue-culture subunit susp pref syringe 0.5 mL)	Flu Vaccine	7/12/26
FLULAVAL 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/26/26
FLUMIST NASAL VACCINE 2026-2027 (influenza virus vaccine live intranasal liquid)	Flu Vaccine	8/2/26
FLUZONE 2026-2027 (influenza virus vaccine split IM susp)	Flu Vaccine	7/19/26
FLUZONE 2026-2027 (influenza virus vaccine split PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26

PERFORMANCE SELECT BIOSIMILAR DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
FLUZONE HIGH-DOSE 2026-2027 (influenza virus vaccine split high-dose PF susp pref syringe 0.5 mL)	Flu Vaccine	7/19/26
FUROSCIX READYFLOW (furosemide subcutaneous soln auto-injector 80 mg/mL)	Fluid Overload Congestion Due to Heart Failure	8/9/26
HYRNUO (sevabertinib tab 10 mg)	Cancer	8/1/26
MFLUSIVA 2026-27 (influenza virus vaccine type a & b mrna susp pref syringe 0.38 mL)	Flu Vaccine	8/9/26
MYQORZO (aficamten tab 5 mg, 10 mg, 15 mg, 20 mg)	Obstructive hypertrophic cardiomyopathy	9/1/26
PENICILLIN V POTASSIUM (penicillin v potassium for soln 125 mg/5 mL, 250 mg/5 mL)	Bacterial Infections	8/16/26
rifapentine tab 150 mg	Tuberculosis	8/2/26
sitagliptin phosphate-metformin hcl tab ER 24 hr 50-500 mg, 50-1000 mg, 100-1000 mg	Type 2 diabetes mellitus	8/2/26
SKYRIZI (risankizumab-rzaa soln prefilled syringe 55 mg/0.37 mL)	Autoimmune Disorders	7/12/26
TRYNGOLZA (olezarsen sod subcut soln auto-inject 50 mg/0.8 mL (base equivalent))	Familial chylomicronemia syndrome	7/5/26
UPTRAVI (selexipag tab 100 mcg, 150 mcg)	Pulmonary Arterial Hypertension	8/2/26
ZYCUBO (copper histidinate for subcutaneous soln 2.9 mg)	Menkes disease	9/1/26

BASIC, BASIC ANNUAL, BASIC MULTI-TIER, BASIC MULTI-TIER ANNUAL, ENHANCED, ENHANCED ANNUAL AND ENHANCED MULTI-TIER ANNUAL DRUG LIST ADDITIONS		
DRUG ¹	CONDITION	EFFECTIVE DATE
BESREMI PEN (ropeginterferon alfa-2b-njft soln pen inj 500 mcg/0.5ml)	Polycythemia vera	7/19/2026
SKYRIZI (risankizumab-rzaa soln prefilled syringe 55 mg/0.37ml)	Autoimmune Disorders	7/12/2026
TRYNGOLZA (olezarsen sod subcut soln auto-inject 50 mg/0.8ml (base equivalent))	Familial Chylomicronemia Syndrome	7/05/2026
UPTRAVI (selexipag tab 100 mcg, 150 mcg)	Pulmonary arterial hypertension	8/02/2026
ZYCUBO (copper histidinate for subcutaneous soln 2.9 mg)	Menkes Disease	9/1/2026

Drug Tier Changes

The tier changes listed below apply to members on a managed drug list. Tier changes effective Oct. 1, 2026, are listed below.

BALANCED DRUG LIST TIER CHANGES		
DRUG ¹	CONDITION	NEW TIER
INGREZZA (valbenazine tosylate cap 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate cap therapy pack 40 mg (7) & 80 mg (21))	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate capsule sprinkle 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand

BALANCED BIOSIMILAR DRUG TIER CHANGES		
DRUG ¹	CONDITION	EFFECTIVE DATE
INGREZZA (valbenazine tosylate cap 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate cap therapy pack 40 mg (7) & 80 mg (21))	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate capsule sprinkle 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand

PERFORMANCE AND PERFORMANCE ANNUAL DRUG LIST TIER CHANGES		
DRUG ¹	CONDITION	NEW TIER
INGREZZA (valbenazine tosylate cap 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate cap therapy pack 40 mg (7) & 80 mg (21))	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate capsule sprinkle 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand

PERFORMANCE BIOSIMILAR DRUG TIER CHANGES		
DRUG ¹	CONDITION	NEW TIER
INGREZZA (valbenazine tosylate cap 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate cap therapy pack 40 mg (7) & 80 mg (21))	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate capsule sprinkle 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand

PERFORMANCE SELECT DRUG LIST TIER CHANGES		
DRUG ¹	CONDITION	NEW TIER
INGREZZA (valbenazine tosylate cap 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate cap therapy pack 40 mg (7) & 80 mg (21))	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate capsule sprinkle 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand

PERFORMANCE SELECT BIOSIMILAR DRUG TIER CHANGES		
DRUG ¹	CONDITION	NEW TIER
INGREZZA (valbenazine tosylate cap 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate cap therapy pack 40 mg (7) & 80 mg (21))	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand
INGREZZA (valbenazine tosylate capsule sprinkle 40 mg, 60 mg, 80 mg)	Tardive Dyskinesia, Chorea associated with Huntington's Disease	Preferred Brand

Other Tier Changes

Most tier changes become effective quarterly, however, some drugs are moved to a new tier as part of formulary maintenance or re-evaluated during the quarter. Those drugs are listed below with their effective date.

BALANCED DRUG LIST TIER CHANGES			
DRUG ¹	CONDITION	NEW TIER	EFFECTIVE DATE
fenoprofen calcium cap 300 mg	Pain, Osteoarthritis, Rheumatoid Arthritis	Preferred Brand	8/9/2026
propranolol hcl oral soln 20 mg/5 mL	Hypertension, Infantile Hemangiomas	Preferred Generic	8/9/2026
trihexyphenidyl hcl oral soln 0.4 mg/mL	Parkinson's disease	Non-Preferred Generic	8/2/2026

BALANCED BIOSIMILAR DRUG LIST TIER CHANGES			
DRUG ¹	CONDITION	NEW TIER	EFFECTIVE DATE
fenoprofen calcium cap 300 mg	Pain, Osteoarthritis, Rheumatoid Arthritis	Preferred Brand	8/9/2026
propranolol hcl oral soln 20 mg/5 mL	Hypertension, Infantile Hemangiomas	Preferred Generic	8/9/2026
trihexyphenidyl hcl oral soln 0.4 mg/mL	Parkinson's disease	Non-Preferred Generic	8/2/2026

PERFORMANCE DRUG LIST TIER CHANGES			
DRUG ¹	CONDITION	NEW TIER	EFFECTIVE DATE
propranolol hcl oral soln 20 mg/5 mL	Hypertension, Infantile Hemangiomas	Preferred Generic	8/9/2026
trihexyphenidyl hcl oral soln 0.4 mg/mL	Parkinson's disease	Non-Preferred Generic	8/2/2026

PERFORMANCE BIOSIMILAR DRUG LIST TIER CHANGES			
DRUG ¹	CONDITION	NEW TIER	EFFECTIVE DATE
propranolol hcl oral soln 20 mg/5 mL	Hypertension, Infantile Hemangiomas	Preferred Generic	8/9/2026
trihexyphenidyl hcl oral soln 0.4 mg/mL	Parkinson's disease	Non-Preferred Generic	8/2/2026

PERFORMANCE FULL DRUG LIST TIER CHANGES			
DRUG ¹	CONDITION	NEW TIER	EFFECTIVE DATE
propranolol hcl oral soln 20 mg/5 mL	Hypertension, Infantile Hemangiomas	Preferred Generic	8/9/2026
trihexyphenidyl hcl oral soln 0.4 mg/mL	Parkinson's disease	Non-Preferred Generic	8/2/2026

PERFORMANCE SELECT DRUG LIST TIER CHANGES			
DRUG ¹	CONDITION	NEW TIER	EFFECTIVE DATE
propranolol hcl oral soln 20 mg/5 mL	Hypertension, Infantile Hemangiomas	Preferred Generic	8/9/2026
trihexyphenidyl hcl oral soln 0.4 mg/mL	Parkinson's disease	Non-Preferred Generic	8/2/2026

PERFORMANCE SELECT BIOSIMILAR DRUG LIST TIER CHANGES			
DRUG ¹	CONDITION	NEW TIER	EFFECTIVE DATE
propranolol hcl oral soln 20 mg/5 mL	Hypertension, Infantile Hemangiomas	Preferred Generic	8/9/2026
trihexyphenidyl hcl oral soln 0.4 mg/mL	Parkinson's disease	Non-Preferred Generic	8/2/2026

Utilization Management Program Changes

Utilization Management programs are implemented to regularly review the appropriateness of medications within drug-therapy programs, and as a result, may adjust dispensing limits, prior authorization or step-therapy requirements. The following drug programs reflect those changes.

Standard Utilization Management Program Updates

Prior Authorization and Step Therapy programs for standard-pharmacy benefit plans correlate to a member's drug list. Not all standard programs apply since updates are based on the member's current drug list. The prescription drugs tab on bcbstx.com lists the current drug lists and dispensing limits. Members may also log in to [Blue Access for MembersSM](#) or MyPrime.com for more online resources.

Please Note: The PA and ST programs for standard pharmacy benefit plans correlate to a member's drug list. Not all standard PA and ST programs may apply, based on the member's current drug list. A list of PA and ST programs per drug list is posted on the member pharmacy programs section of bcbstx.com.

If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card or log into any of the online resources.

Program Updates

The following standard utilization management programs were updated on the dates indicated below.

PROGRAM NAME	PROGRAM TYPE	CHANGES MADE	DRUG LISTS	EFFECTIVE DATE
Therapeutic Alternatives PAQL	Prior authorization, Dispensing Limits	Removed SITAVIG (acyclovir) 50 mg buccal tab	Basic, Basic Multi-Tier, Enhanced, Enhanced Multi-Tier, Basic Annual, Basic Multi-Tier Annual, Enhanced Annual, Enhanced Multi-Tier Annual, HIM, Balanced, Performance, Performance Annual, Performance Full, Performance Select, Balanced Biosimilar, Performance Biosimilar, Performance Select Biosimilar	10/1/2026
Non-Preferred Brand Alternatives PAQL	Prior Authorization Dispensing Limits	Removed LASTACFT and MIRVASO	HIM	10/1/2026

Dispensing Limit Changes

The prescription-drug benefit program BCBSTX includes coverage limits on certain medications and drug categories. Dispensing limits are based on U.S. Food and Drug Administration approved dosage regimens and product labeling.

Dispensing Limit changes are listed below with their effective date.

View the most up-to-date drug list and list of drug dispensing limits, visit the [provider pharmacy webpage](#). If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card. Members may also log in to [Blue Access for MembersSM](#) or [MyPrime.com](#) for more online resources.

BASIC, BASIC MULTI-TIER, ENHANCED, ENHANCED MULTI-TIER, BASIC ANNUAL, BASIC MULTI-TIER ANNUAL, ENHANCED ANNUAL, ENHANCED MULTI-TIER ANNUAL, HIM, BALANCED, PERFORMANCE, PERFORMANCE ANNUAL, PERFORMANCE FULL, PERFORMANCE SELECT DRUG LISTS			
MEDICATION(S) ¹	CLINICAL PROGRAM	NEW DISPENSING LIMIT	EFFECTIVE DATE
FILSPARI (sparsentan) 400 mg tab	Filspari PAQL	60 tabs per 30 days	9/15/2026
LEDERLE LEUCOVORINE (Leucovorin calcium) 5 mg tab	Leucovorin PAQL	180 tabs per 30 days	9/15/2026
Leucovorin calcium 10 mg tab, 15 mg tab	Leucovorin PAQL	180 tabs per 30 days	9/15/2026
Leucovorin calcium 25 mg tab	Leucovorin PAQL	360 tabs per 30 days	9/15/2026
SITAVIG (acyclovir) 50 mg buccal tab	Therapeutic Alternatives PAQL	Dispensing limit retired	10/1/2026
VYSCOXA (celebrex) 10 mg/mL oral susp	Alternative Dosage Form PAQL	1200 mL per 30 days	10/1/2026

BALANCED BIOSIMILAR, PERFORMANCE BIOSIMILAR, PERFORMANCE SELECT BIOSIMILAR			
MEDICATION(S) ¹	CLINICAL PROGRAM	NEW DISPENSING LIMIT	EFFECTIVE DATE
FILSPARI (sparsentan) 400 mg tab	Filspari PAQL	60 tabs per 30 days	9/15/2026
LEDERLE LEUCOVORINE (Leucovorin calcium) 5 mg tab	Leucovorin PAQL	180 tabs per 30 days	9/15/2026
Leucovorin calcium 10 mg tab, 15 mg tab	Leucovorin PAQL	180 tabs per 30 days	9/15/2026
Leucovorin calcium 25 mg tab	Leucovorin PAQL	360 tabs per 30 days	9/15/2026
SITAVIG (acyclovir) 50 mg buccal tab	Therapeutic Alternatives PAQL	Dispensing limit retired	10/1/2026
VYSCOXA (celebrex) 10 mg/mL oral susp	Alternative Dosage Form PAQL	1200 mL per 30 days	10/1/2026

Change in Benefit Coverage for Select High-Cost Products

Several high-cost products with available lower cost alternatives will be excluded on the pharmacy benefit for select drug lists. This change impacts BCBSTX members who have prescription-drug benefits administered by Prime Therapeutics[†]. This change is part of an ongoing effort to ensure our members and employer groups have access to safe, cost-effective medications.

Please note: Members were not notified of this change because either there is no utilization, or the pharmacist can easily fill a member's prescription with the equivalent without needing a new prescription from the doctor.

The following drugs are excluded on select drug lists.

PRODUCT(S) NO LONGER COVERED ¹	COVERED ALTERNATIVE(S) ^{1, 2}	CONDITION
COMBOGESIC (ibuprofen-acetaminophen tab 97.5-325 mg) AFT Pharmaceuticals	OTC alternatives of individual ingredients	Pain
NATALCORE CHW Blue Heron Pharmaceuticals	Amneal Prenatal+, Prenatal19, Prenatal-U, SE-Natal, Trinate	Pre-natal care
tolmetin sodium tab 200 mg Chartwell Rx	meloxicam, ibuprofen, naproxen	Pain
MATRIAPRO CHEW Trivia Pharmaceuticals	Amneal Prenatal+, Prenatal19, Prenatal-U, SE-Natal, Trinate	Pre-natal care
fenoprofen cap 300 mg Coral Way Pharma	MELOXICAM, IBUPROFEN, NAPROXEN	Pain
hydrocortisone acetate cream 2.5% Allegis Pharmaceuticals	non-acetate salt formulation, hydrocortisone cream 2.5%	Rash or allergic reaction
Gabapentin cap 200 mg Trifluent Pharma	other generic gabapentin capsule strengths	Nerve pain or seizures
Prenacore Chewable Tablets Krewe Pharma	Amneal Prenatal+, Prenatal19, Prenatal-U, SE-Natal, Trinate	Pre-natal care

¹Third-party brand names are the property of their respective owner.

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

⁴This drug is based on group-specific coverage. Members should refer to their benefit materials for coverage details or call the number on their member ID card.

Please note: If coverage of the member's medication is changed on their prescription drug list, the amount the member will pay for the same medication under this preventive drug benefit may also change.

[†]Prime Therapeutics LLC is a separate company contracted by BCBSTX to provide pharmacy solutions. BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

^{**}SortPak Pharmacy is an independent pharmacy that contracts with CivicaScript® to provide mail order prescription drug services. SortPak Pharmacy is independent from and not affiliated with BCBSTX.

MyPrime.com is a pharmacy-benefit website owned and operated by Prime Therapeutics LLC.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.